Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2008-04-01
2008-04-01
Kennedy, Sharon E. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
Reexamination Certificate
active
07351421
ABSTRACT:
A method for treating vulnerable plaques of a patient, comprising: providing a biodegradable stent comprising a first supporting zone made of a first biodegradable material, wherein the supporting zone comprises at least a portion of continuous circumference of the stent; and a second therapeutic zone made of a second biodegradable material, wherein the therapeutic zone comprises at least one bioactive agent; delivering the biodegradable stent to the vulnerable plaques; orienting the therapeutic zone at about the luminal surface of the vulnerable plaque; and releasing the at least one bioactive agent for treating the vulnerable plaques.
REFERENCES:
patent: 4806595 (1989-02-01), Noishiki et al.
patent: 5037664 (1991-08-01), Kyogoku et al.
patent: 5085629 (1992-02-01), Goldberg et al.
patent: 5270446 (1993-12-01), Kyogoku et al.
patent: 5290271 (1994-03-01), Jernberg
patent: 5322935 (1994-06-01), Smith
patent: 5464450 (1995-11-01), Buscemi et al.
patent: 5516781 (1996-05-01), Morris et al.
patent: 5545208 (1996-08-01), Wolff et al.
patent: 5693085 (1997-12-01), Buirge et al.
patent: 5733327 (1998-03-01), Igaki et al.
patent: 5780052 (1998-07-01), Khaw et al.
patent: 5929038 (1999-07-01), Chang
patent: 6045568 (2000-04-01), Igaki et al.
patent: 6071305 (2000-06-01), Brown et al.
patent: 6080177 (2000-06-01), Igaki et al.
patent: 6103255 (2000-08-01), Levene et al.
patent: 6120535 (2000-09-01), McDonald et al.
patent: 6160084 (2000-12-01), Langer et al.
patent: 6162826 (2000-12-01), Moon et al.
patent: 6200335 (2001-03-01), Igaki
patent: 6206931 (2001-03-01), Cook et al.
patent: 6245103 (2001-06-01), Stinson
patent: 6262083 (2001-07-01), Moon et al.
patent: 6264992 (2001-07-01), Voytik-Harbin et al.
patent: 6388043 (2002-05-01), Langer et al.
patent: 6395300 (2002-05-01), Straub et al.
patent: 6423682 (2002-07-01), Ballinger et al.
patent: 6436703 (2002-08-01), Tang et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6475784 (2002-11-01), Papkoff
patent: 6476211 (2002-11-01), Ford et al.
patent: 6485920 (2002-11-01), Ballinger et al.
patent: 6544544 (2003-04-01), Hunter et al.
patent: 6608040 (2003-08-01), Lin et al.
patent: 6624138 (2003-09-01), Sung et al.
patent: 6632242 (2003-10-01), Igaki
patent: 6699280 (2004-03-01), Camrud et al.
patent: 6806257 (2004-10-01), Lee et al.
patent: 6827737 (2004-12-01), Hill et al.
patent: 2001/0034550 (2001-10-01), Buirge et al.
patent: 2002/0058986 (2002-05-01), Landau et al.
patent: 2002/0082680 (2002-06-01), Shanley et al.
patent: 2002/0133223 (2002-09-01), Vito et al.
patent: 2003/0004568 (2003-01-01), Ken et al.
patent: 2003/0055198 (2003-03-01), Langer et al.
patent: 2003/0109442 (2003-06-01), Bisgaier et al.
patent: 2003/0135265 (2003-07-01), Stinson
patent: 2003/0153972 (2003-08-01), Helmus
patent: 2004/0015187 (2004-01-01), Lendlein et al.
patent: 2004/0024448 (2004-02-01), Chang et al.
patent: 2004/0034409 (2004-02-01), Heublein et al.
patent: 2004/0039441 (2004-02-01), Rowland et al.
patent: 2004/0142014 (2004-07-01), Litvack et al.
patent: 2004/0142902 (2004-07-01), Struijker- Boudier
patent: 2004/0202692 (2004-10-01), Shanley et al.
patent: 2004/0215338 (2004-10-01), Elkins et al.
patent: 2004/0220660 (2004-11-01), Shanley et al.
patent: 2004/0220665 (2004-11-01), Hossainy et al.
patent: 2005/0119723 (2005-06-01), Peacock, III
patent: 2005/0163818 (2005-07-01), Sung et al.
patent: 2005/0233992 (2005-10-01), Itescu
patent: 2006/0034885 (2006-02-01), Sung et al.
patent: 2006/0095058 (2006-05-01), Sivan et al.
patent: 2006/0287710 (2006-12-01), Lendlein et al.
patent: 2007/0078513 (2007-04-01), Campbell
patent: 2007/0141100 (2007-06-01), Sung et al.
Radar DS, “High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis”, JAMA 2003;290(17): 2322-2324.
Nissen SE et al., “Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Symdroms”, JAMA 2003; 290(17): 2292-2300.
Naghavi M et al., “From Vulnerable Plaque to Vulnerable Patient-Part I” Circulation 2003; 108: 1664-1672.
Naghavi M et al., “From Vulnerable Plaque to Vulnerable Patient—Part II” Circulation 2003; 108: 1772-1778.
Sung HW et al., “Feasibility Study of a Natural Crosslinking Reagent for Biological Tissue Fixation” J Biomed Mater Res 1998; 42: 560-567.
Huang LL et al., “Biocompatibility Study of a Biological Tissue Fixed With a Naturally Occurring Crosslinking Reagent” J Biomed Mater Res 1998; 42: 568-576.
Sung HW et al., “In Vitro Evaluation of Cytotoxicity of a Naturally Occurring Cross-Linking Reagent for Biological Tissue Fixation”, J Biomater Sci Polymer Edn 1999; 10(1): 63-78.
Sung HW et al., “A Naturally Occurring Reagent for Biological Tissue Fixation” in New Biomedical Materials, Edited by Haris PI and Chapman D, pp. 182-191 (1998), Published by IOS Press.
Sung HW et al., “Crosslinking Characteristics and Mechanical Properties of a Bovine Pericardium Fixed With a Naturally Occurring Crosslinking Agent” J Biomed Mater Res 1999; 47: 116-126.
Sung HW et al., “Mechanical Properties of a Porcine Aortic Valve Fixed With a Naturally Occurring Crosslinking Agent” Biomaterials 1999; 20: 1759-1772.
Sung HW et al., “In Vitro Surface Characterization of a Biological Patch Fixed With a Naturally Occurring Crosslinking Agent” Biomaterials 2000; 21: 1353-1362.
Tsai CC et al., “In Vitro Evaluation of the Genotoxicity of a Naturally Occurring Crosslinking Agent (Genipin) for Biologic Tissue Fixation” J Biomed Mater Res 2000; 52: 58-65.
Sung HW et al., “Fixation of Biological Tissues With a Naturally Occurring Crosslinking Agent: Fixation Rate and Effects of PH, Temperature, and Initial Fixative Concentration” J Biomed Mater Res 2000; 52: 77-87.
Sung HW et al., “Extraction of a Naturally Occurring Crosslinking Agent (Genipin) From Gardenia Fruits and its Applications in Biological Tissue Fixation” in Biomaterials and Drug Delivery Toward New Millenium, Edited by Park KD et al., pp. 623-632 (2000), Published by Han Rin Won Publishing Co.
Tsai CC et al., “Effects of Heparin Immobilization on the Surface Characteristics of a Biological Tissue Fixed With a Naturally Occurring Crosslinking Agent” Biomaterials 2001; 22: 523-533.
Sung HW et al., “Stability of a Biological Tissue Fixed With a Naturally Occurring Croslinking Agent (Genipin)” J Biomed Mater Res 2001; 55: 538-546.
Chang Y et al., “Reconstruction of the Right Ventricular Outflow Tract With a Bovine Jugular Vein Graft Fixed With a Naturally Occurring Crosslinking Agent (Genipin) in a Canine Model” J Thorac Cardiovasc Surg 2001; 122: 1208-1218.
Mi FL et al., “In Vivo Biocompatibility and Degradability of a Novel Injectable-Chitosan-Based Implant” Biomaterials 2002; 23: 181-191.
Mi FL et al., “Drug Release From Chitosan-Alginate Complex Beads Reinforced by a Naturally Occurring Cross-Linking Agent” Carbohydrate Polymers 2002; 48: 61-72.
Chang Y et al., “In Vivo Evaluation of Cellular and Acellular Bovine Pericardia Fixed With a Naturally Occurring Crosslinking Agent (Genipin)” Biomaterials 2002; 23: 2447-2457.
Liang HC et al., “Genipin-Crosslinked Gelatin Microspheres as a Drug Carrier for Intramuscular Administration-In Vitro and In Vivo Studies” J Biomed Mater Res 2003; 65A: 271-282.
Biocompatibles “PC Technology Overview” 2004.
News Release “TCT: ABT-578-Eluting Stent Demonstrates Robust Results” Washington DC, Sep. 23, 2003.
News Release “First Human Implant Heralds Next Generation of Coronary Stent System” Santa Rose, CA, Jan. 7, 2003.
News Release “Endeavor I: IVUS Analysis of ABT-578-Eluting Stent Trial Confirms Early Safety” New Orleans, LA, ACC2004.
Chen Mei-Chin
Sung Hsing-Wen
Tu Hosheng
Tu Peter Y
LandOfFree
Drug-eluting stent having collagen drug carrier chemically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug-eluting stent having collagen drug carrier chemically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug-eluting stent having collagen drug carrier chemically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2774209